NF-kappaB activation is required for adaptive cardiac hypertrophy. - Wikidata - awgldk - TriplyDB

NF-kappaB activation is required for adaptive cardiac hypertrophy.

NF-kappaB activation is required for adaptive cardiac hypertrophy.

http://www.wikidata.org/entity/Q45924674

about

A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure.Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts.IKKi deficiency promotes pressure overload-induced cardiac hypertrophy and fibrosis.Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overload Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes Targeting cardiovascular disease with novel SIRT1 pathways.Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression.HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.Regulation of nuclear factor κB (NF-κB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5).Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?Erbin is a negative modulator of cardiac hypertrophy.Oxidative stress and cardiac hypertrophy: a review.Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart?Transcription Factor NF-κB: An Update on Intervention Strategies.Dexamethasone promotes hypertrophy of H9C2 cardiomyocytes through calcineurin B pathway, independent of NFAT activation.An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.Innate immunity and remodelling.Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation.The NF-κB subunit c-Rel stimulates cardiac hypertrophy and fibrosis.Sang-qi Granula Reduces Blood Pressure and Myocardial Fibrosis by Suppressing Inflammatory Responses Associated with the Peroxisome Proliferator-Activated Receptors and Nuclear Factor κ B Protein in Spontaneously Hypertensive Rats.Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis.Renal sympathetic denervation improves myocardial apoptosis in rats with isoproterenol-induced heart failure by downregulation of tumor necrosis factor-α and nuclear factor-κB.NF-κB mediated miR-26a regulation in cardiac fibrosis.Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor R Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways.Pregnancy mitigates cardiac pathology in a mouse model of left ventricular pressure overload.Insights into innate immune signalling in controlling cardiac remodelling.NF-κB-mediated miR-30b regulation in cardiomyocytes cell death by targeting Bcl-2.Short-Term Treatment with Esmolol Reverses Left Ventricular Hypertrophy in Adult Spontaneously Hypertensive Rats via Inhibition of Akt/NF-κB and NFATc4.Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy Inflammation in Right Ventricular Failure: Does It Matter?

P2860

Q28116093-1FCA7E15-A281-49E6-9EA6-C87DB57670D2 Q28583532-7C1B4E11-E3BE-4DA3-8F40-959CE0776546 Q30523246-7886E2A7-ED9F-4C70-B020-43897F8CED89 Q33888579-5D847CB0-CD20-4286-A508-17D25586FD6C Q34562186-F5A6935D-B978-487F-A3A2-1B58B3B24497 Q35002059-675C3BD6-2862-421F-8EBF-2DD40A471A4B Q35404816-71938D90-150B-4723-BD1D-5DA473BE1F29 Q35661632-4B77AA24-A396-4B72-AA99-6E298B70F01B Q35921640-227C6548-6D24-41A0-BD25-D74A1BD9E15E Q36212830-63259098-2E71-4D58-98FD-3BC475D65FB8 Q36674142-A62E7E49-14FC-4398-965B-96E0439639A1 Q37388772-F900CCF2-5BD0-42F8-8298-F74B31BFD5BD Q37723147-A8EC592D-4E47-468A-8C5A-1F34109AF0EA Q37725186-7AEB62D1-A86A-4CAB-A663-43C7D1CB92C7 Q37991019-03FA2440-23A3-471A-A8CA-0EAD01092F4A Q38093421-0B773B7A-841E-4C75-B67B-1420D6718E7D Q38802627-C59D9891-1BF2-4986-B7DC-D0A6FBB393B6 Q38824086-BF05315F-A3B5-45FF-A11F-7F2279D96226 Q39232014-196908DE-3EDC-4056-95B4-51EFD701BB17 Q41208076-9090ECD4-DEFC-4BD7-95CB-771BD7F622A9 Q41572967-662F8550-202D-4FAF-83AC-FE900DA16324 Q41862491-4B9B3854-A461-4197-B5A5-C0953AA2FF05 Q41939566-6A1AEC1E-FDB9-4359-81C7-9E97E8BA3A8A Q42141141-C0E4543E-8365-4593-9C6C-7514CE80F3D1 Q42269363-5DED06E0-4BB4-46B4-BB22-7F2F17DAC098 Q42936835-0B8240C1-5372-497E-B26B-C898CE4D9656 Q46054688-B33EB7DD-F903-4BD1-B376-48BC95311FC0 Q47107119-E934147A-3197-4403-ACBA-A95BE12B69FA Q47276537-4B3E91A6-BB35-4F8A-8BD0-FE9E5E238936 Q48643769-FB186BD0-478C-412C-9CA7-2A482726B78F Q52448624-C8EC8849-405A-438A-BC13-AE89ECEB995F Q53084627-98B19D79-F1D8-4AF3-8F16-A88DB72358AC Q54944403-7982590E-02F9-4A74-A7CA-77A9C643CE82 Q58728912-7EE1A010-AF5C-4B3B-92E9-F5EEA684326A Q58735426-EEEC562F-D709-48B0-8929-7D50DF0B6EAC

P2860

NF-kappaB activation is required for adaptive cardiac hypertrophy.

http://www.wikidata.org/entity/Q45924674

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@en

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@nl

type

label

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@en

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@nl

prefLabel

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@en

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@nl

P1433

Q45924674-4B7F0DCD-ECD3-48CF-ACAB-12EDDA706151

P1476

Q45924674-C09FAC0F-2E13-4D4F-854F-0C647BB7BDB6

P2093

Q45924674-01C6BFE8-CB31-4DC2-9D35-C01F3D8BB7A7

Q45924674-08185334-10D4-4A43-B093-42D75438FDC1

Q45924674-08B6A47B-B805-4F87-8D0C-80EE7CD00F22

Q45924674-10ABCB66-D5D9-4026-8315-7282A62EE5FF

Q45924674-3FC8DAD0-C3BC-49A7-BF93-574A69F728A7

Q45924674-4B475F60-A726-4B9E-B0CF-03E50D57E5E9

Q45924674-7A946499-56D5-4FE3-AC8C-448E67F0C4F2

Q45924674-BB521735-184F-477B-B111-B5317C4D3A41

Q45924674-F29602E5-580A-4615-8741-EF877B0E1111

P2860

Q45924674-0320306E-990D-4B10-BBBC-724B27A448A4

Q45924674-1831588D-2C4F-417F-9E76-6C82A163EDE8

Q45924674-45FF570B-17FB-4227-9771-0C23500BD91C

Q45924674-489CA07F-39F4-4017-A44C-E38BD3A60D9C

Q45924674-77A01812-26B2-4CA4-9B79-43F11E66F4AC

Q45924674-81DDDCC0-9492-4A53-B6C6-595080CABE8B

Q45924674-A428E827-DA95-42EF-817A-EA73D94A8673

Q45924674-AE7DB852-C036-4CE2-B24B-4CE2AB642E15

Q45924674-C8591F86-D8C3-4577-8750-AE937E7241CD

Q45924674-D270D3BD-3985-4E32-9703-BDC13C3A2D31

P304

Q45924674-D70DE680-0402-4A35-8E50-EBDE6F35E6BB

P31

Q45924674-4CE34046-BA65-473F-8285-2764984855DF

P356

Q45924674-9327E102-4177-4E0E-ABE6-2408A3224A7B

P433

Q45924674-93ACC0B8-8D08-4604-BD48-D23B549D36A9

P478

Q45924674-87CFE661-F1DC-4C37-8F11-E099C5FF2EBC

P577

Q45924674-999F268A-4603-4321-994E-242F4D8E911F

P698

Q45924674-D21E95A9-695F-4B77-9B50-3DF2E0304CC8

P921

Q45924674-1411EF6A-360E-403A-B20F-81B9F0648005

P356

P1433

Cardiovascular Research

P1476

NF-kappaB activation is required for adaptive cardiac hypertrophy.

@en

P2093

Anke Renger

http://www.w3.org/2001/XMLSchema#string

Christina Gehrke

http://www.w3.org/2001/XMLSchema#string

Claudia Noack

http://www.w3.org/2001/XMLSchema#string

Laura Zelarayan

http://www.w3.org/2001/XMLSchema#string

Leon de Windt

http://www.w3.org/2001/XMLSchema#string

Maria-Patapia Zafiriou

http://www.w3.org/2001/XMLSchema#string

Martin W Bergmann

http://www.w3.org/2001/XMLSchema#string

Rainer Dietz

http://www.w3.org/2001/XMLSchema#string

Roel van der Nagel

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-catenin downregulation is required for adaptive cardiac remodeling

Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

The fuzzy logic of physiological cardiac hypertrophy.

Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice.

Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats.

Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload.

Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo.

P304

416-424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVP237

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19620128

http://www.w3.org/2001/XMLSchema#string

P921